Last updated: September 9, 2026
ACTHREL, the brand name for corticorelin ovine triflutate, is a synthetic corticotropin-releasing hormone peptide used as a diagnostic aid in evaluating ACTH-dependent Cushing syndrome. Its commercial opportunity was limited by narrow utilization, specialist administration, competition from established diagnostic algorithms, and the absence of a recurring-treatment market. Public FDA and DailyMed records identify ACTHREL as discontinued, and no reliable public source reports standalone sales or current commercial activity.[1,2]
What is ACTHREL and what was it approved to do?
ACTHREL is an injectable synthetic analogue of ovine corticotropin-releasing factor. It stimulates pituitary corticotroph cells to release ACTH and is used during endocrine testing.
| Attribute |
ACTHREL |
| Active ingredient |
Corticorelin ovine triflutate |
| Brand |
ACTHREL |
| Drug type |
Synthetic peptide diagnostic agent |
| Route |
Intravenous injection |
| Primary use |
Diagnostic evaluation of ACTH-dependent Cushing syndrome |
| FDA status |
FDA-approved product; publicly listed as discontinued |
| Original sponsor/commercial company |
Ferring Pharmaceuticals |
| Therapeutic market |
Endocrinology diagnostics |
| Recurring treatment use |
None |
| Biosimilar relevance |
Low; ACTHREL is not a conventional therapeutic monoclonal biologic |
The product was intended to help distinguish pituitary ACTH secretion from ectopic ACTH secretion. The test was not a treatment for hypercortisolism. Its commercial value therefore depended on diagnostic volume rather than chronic prescription use.[1]
When did ACTHREL receive FDA approval and lose exclusivity?
ACTHREL received U.S. approval in 1999, according to the product labeling. Any U.S. regulatory exclusivity associated with that approval has expired. The product’s commercial position is now determined by clinical adoption, manufacturing availability, and diagnostic alternatives rather than by meaningful regulatory exclusivity.[1]
ACTHREL exclusivity timeline
| Milestone |
Timing |
Commercial significance |
| FDA approval |
1999 |
Authorized use as a diagnostic aid |
| Marketed by Ferring |
Post-approval period |
Established a branded specialist diagnostic product |
| Patent and regulatory exclusivity period |
Expired |
No longer protects a premium branded position |
| Public FDA/DailyMed discontinued status |
Current public records |
Indicates no normal commercial supply from the original product listing |
The exact patent portfolio is difficult to connect to current commercial rights because ACTHREL is no longer an active marketed product and public records do not identify a current, enforceable U.S. patent barrier that would prevent competing production. The original composition and use protection would also be expected to have expired given the 1999 approval date.
What is the Orange Book status of ACTHREL?
ACTHREL’s Orange Book relevance is limited because the product is listed as discontinued in public FDA drug databases. A discontinued listing does not necessarily mean the underlying approval has been formally withdrawn for safety or efficacy reasons. It indicates that the product is no longer marketed under the relevant FDA product listing.[2,3]
The key commercial implications are:
- No active branded launch platform is evident.
- No meaningful listed patent-term barrier is expected to block a competing product.
- A generic applicant would still need to address sterile injectable manufacturing, peptide characterization, clinical diagnostic performance, and FDA approval requirements.
- Regulatory feasibility does not guarantee commercial viability because the addressable market is small.
The absence of an active commercial product also reduces the value of an Orange Book litigation strategy. A Paragraph IV challenge is unlikely to be economically attractive against an inactive branded product unless a successor product, authorized generic, or revived commercial program appears.
What market did ACTHREL serve?
ACTHREL operated in a narrow diagnostic market centered on ACTH-dependent Cushing syndrome. The relevant patients represent a subset of all patients evaluated for hypercortisolism. Most diagnostic pathways begin with biochemical confirmation of Cushing syndrome and then use ACTH measurement, high-dose dexamethasone suppression, inferior petrosal sinus sampling, pituitary imaging, and evaluation for ectopic ACTH sources.[4,5]
Addressable market limitations
ACTHREL’s market had several structural constraints:
- Cushing syndrome is rare relative to common endocrine disorders.
- Only a portion of suspected cases require dynamic CRH stimulation.
- Endocrinologists can use other diagnostic tests and imaging pathways.
- The product was administered in specialist settings rather than dispensed through retail pharmacies.
- The test produced episodic revenue rather than chronic treatment revenue.
- Hospitals and specialty centers could face procurement and reimbursement hurdles.
These conditions limit both unit volume and pricing power. A diagnostic peptide can command a high price per vial while still generating modest annual revenue because the number of eligible tests is low.
What competing diagnostics affected ACTHREL demand?
ACTHREL competed with diagnostic methods rather than with another large branded chronic therapy.
| Diagnostic approach |
Role in Cushing evaluation |
Effect on ACTHREL |
| Plasma ACTH measurement |
Initial classification of ACTH-dependent disease |
Reduced need for additional stimulation in some patients |
| Low-dose dexamethasone suppression |
Screening for cortisol excess |
Used earlier in the diagnostic sequence |
| High-dose dexamethasone suppression |
Historical differentiation of pituitary disease |
Could substitute for or complement CRH testing |
| Inferior petrosal sinus sampling |
Localization of pituitary ACTH secretion |
More invasive but often decisive in difficult cases |
| Pituitary MRI |
Structural localization |
Supports diagnosis but does not replace biochemical testing |
| Ectopic ACTH evaluation |
Search for nonpituitary source |
Redirects workup away from CRH stimulation |
| Corticotropin-releasing hormone testing using other sources |
Diagnostic stimulation |
Potential substitute where available |
Clinical guidelines have recognized CRH stimulation as one component of a broader diagnostic workup, not as a universal test for all patients with suspected Cushing syndrome.[4,5] The resulting market was therefore highly selective.
How did ACTHREL’s financial trajectory develop?
ACTHREL’s financial trajectory was likely characterized by limited launch revenue, low-volume specialist adoption, and eventual commercial withdrawal. Ferring is privately held and does not provide a publicly reported product-level income statement for ACTHREL. No reliable standalone revenue series, prescription count, gross margin, or annual unit-sales disclosure is available in the principal public regulatory sources.
Financial trajectory by phase
| Phase |
Business condition |
Expected financial effect |
| Launch and early commercialization |
New diagnostic option for endocrine specialists |
Initial sales from referral centers and academic hospitals |
| Specialist adoption |
Narrow use in selected ACTH-dependent Cushing cases |
Low unit volume with potentially high price per diagnostic vial |
| Mature market |
Competition from alternative testing and clinical practice variation |
Limited growth and weak operating leverage |
| Supply or commercial discontinuation |
Product no longer broadly marketed |
Revenue falls toward zero |
| Post-discontinuation |
No established recurring sales base |
Asset value depends on redevelopment, licensing, or replacement supply |
The product’s economics were unfavorable compared with chronic endocrine drugs. A chronic therapy can generate repeated prescriptions from each treated patient. ACTHREL generated revenue only when a clinician ordered a specialized diagnostic procedure. That model creates low patient lifetime value and makes sales infrastructure expensive relative to demand.
What patent protection covered ACTHREL?
ACTHREL’s protection would have been based primarily on peptide composition, formulation, manufacturing, and diagnostic use. Publicly available current records do not show a material unexpired U.S. patent estate that would support an active exclusivity premium.
Potential historical protection categories
Composition patents
Composition claims could have covered corticorelin ovine triflutate or related peptide structures. Such claims are generally most valuable before competing synthesis routes and alternative peptide formulations become available.
Formulation patents
A sterile injectable peptide product can be protected through claims covering:
- Peptide concentration
- Buffer composition
- Stabilizers
- Freeze-drying or reconstitution
- Container-closure systems
- Storage conditions
- Intravenous administration parameters
Formulation protection would have been commercially relevant only if the claims remained enforceable and difficult to design around. No current public evidence indicates that formulation patents create a significant barrier to a new ACTHREL-like product.
Method-of-use patents
Potential use claims could cover administering corticorelin to differentiate pituitary ACTH secretion from ectopic ACTH secretion. These claims would have faced practical limits because diagnostic methods may use multiple biomarkers and imaging techniques, and because a new entrant could potentially pursue narrower or non-infringing diagnostic protocols.
Manufacturing and process protection
Peptide synthesis, purification, impurity control, and sterile filling are operationally important. Process know-how may be more relevant than expired composition claims for a successor product. A new manufacturer would need reproducible control of peptide identity, purity, aggregation, endotoxin levels, sterility, and stability.
Is there biosimilar risk for ACTHREL?
Traditional biosimilar risk is low because ACTHREL is a synthetic peptide diagnostic product, not a conventional therapeutic protein approved under a BLA. A competing product would more likely require an abbreviated or full drug-approval pathway based on the final FDA classification, reference-product status, and available regulatory precedents.
The principal competitive risk is therefore generic or follow-on peptide entry, not biosimilar substitution. The barriers include:
- Demonstrating pharmaceutical equivalence
- Establishing peptide purity and sequence identity
- Matching injectable formulation performance
- Validating sterile manufacturing
- Demonstrating stability and container compatibility
- Addressing clinical performance in the intended diagnostic setting
These are real manufacturing barriers, but they are not equivalent to an active patent barrier.
Which companies are challenging ACTHREL?
No significant public Paragraph IV campaign or active U.S. patent litigation involving ACTHREL is identified in the principal FDA and public product records. The absence of litigation is consistent with the product’s discontinued status and small addressable market.
Potential competition would come from three groups:
- Specialty peptide manufacturers capable of producing sterile injectable diagnostic agents.
- Compounding or hospital-based sources, where legally and clinically appropriate.
- Diagnostic laboratories and academic centers using alternative localization protocols.
The third group is commercially important because ACTHREL’s main competitive threat was substitution at the diagnostic-workflow level rather than direct branded competition.
What generic launch scenarios exist for ACTHREL?
A new ACTHREL-like product would face three possible launch scenarios.
Scenario 1: Full commercial reintroduction
A manufacturer could relaunch corticorelin as a niche diagnostic product through endocrinology and academic-hospital channels. Success would require reliable supply, reimbursement support, clinical education, and inclusion in specialist protocols.
Scenario 2: Limited specialty supply
A manufacturer could target a small number of referral centers performing complex Cushing syndrome evaluations. This approach would reduce sales costs but would also limit revenue and make manufacturing scale difficult.
Scenario 3: No commercial relaunch
Hospitals and specialists could continue using alternative diagnostic strategies, leaving insufficient demand to support a dedicated commercial product. This is the most consistent scenario with the product’s discontinued status.
How strong is the ACTHREL patent estate?
The current patent estate appears commercially weak.
| Factor |
Assessment |
| Patent age |
Weak, based on 1999 approval timing |
| Current Orange Book leverage |
Limited |
| Active litigation |
No material public dispute identified |
| Formulation protection |
Potentially relevant historically, but no current barrier identified |
| Method-of-use protection |
Narrow commercial value |
| Manufacturing know-how |
More important than patent exclusivity for a successor |
| Regulatory exclusivity |
Expired |
| Biosimilar protection |
Not applicable in the conventional sense |
| Generic threat |
Technically feasible but commercially limited |
The principal barrier is demand, not intellectual property. A follow-on manufacturer could encounter development and quality-control costs that are disproportionate to the available market.
What is ACTHREL’s current commercial outlook?
ACTHREL has minimal current commercial value as an active branded product. Its potential value lies in one of four areas:
- Reintroduction as a niche diagnostic product
- Licensing of peptide manufacturing or formulation know-how
- Use as a reference for development of a related CRH diagnostic
- Strategic supply to academic endocrine centers
A relaunch would need to overcome an unfavorable cost structure. The product would require validated sterile production, regulatory maintenance, specialized sales coverage, and reimbursement support. Without evidence of a substantial increase in complex Cushing syndrome testing, recurring revenue would likely remain limited.
How does ACTHREL compare with chronic endocrine drugs?
| Metric |
ACTHREL |
Chronic endocrine therapy |
| Treatment purpose |
Diagnosis |
Disease management |
| Dosing frequency |
One-time or episodic testing |
Repeated dosing |
| Patient lifetime value |
Low |
Moderate to high |
| Prescriber base |
Endocrinologists and referral centers |
Broader specialist and primary-care networks |
| Refill potential |
None |
Recurring |
| Market size |
Narrow |
Usually broader |
| Manufacturing |
Sterile peptide injectable |
Varies by product |
| Commercial risk |
Demand concentration and supply economics |
Adherence, competition, pricing, and reimbursement |
| IP value |
Historically time-limited |
Often supported by multiple formulation and use patents |
This comparison explains why ACTHREL could be clinically useful but financially unattractive. Its revenue model lacked the repeat-purchase economics that support large pharmaceutical franchises.
Key Takeaways
- ACTHREL is corticorelin ovine triflutate, an injectable diagnostic peptide for selected Cushing syndrome evaluations.
- FDA approval dates to 1999, and regulatory exclusivity is long expired.[1]
- Public FDA and DailyMed records identify the product as discontinued.[2,3]
- No reliable public source reports standalone ACTHREL revenue or current sales.
- The product’s market was constrained by rare disease prevalence, specialist administration, and competing diagnostic methods.
- Patent risk appears low; manufacturing, sterile supply, and regulatory execution are more important barriers.
- Biosimilar competition is not the primary issue because ACTHREL is a synthetic peptide diagnostic rather than a conventional therapeutic biologic.
- A successor product could target referral centers, but the commercial opportunity would remain niche.
- The financial trajectory is best characterized as limited specialist revenue followed by commercial withdrawal, with no visible active branded revenue base.
FAQs About ACTHREL
Is ACTHREL still available in the United States?
Public FDA and DailyMed records list ACTHREL as discontinued. It is not positioned as a normally marketed U.S. product.[2,3]
What disease was ACTHREL used to diagnose?
ACTHREL was used as a diagnostic aid in evaluating ACTH-dependent Cushing syndrome, particularly when clinicians needed additional information about pituitary versus ectopic ACTH secretion.
Does ACTHREL have a biosimilar competitor?
No conventional biosimilar competition is established. A future competitor would more likely be a follow-on synthetic peptide or generic-like injectable product.
Why did ACTHREL have limited commercial potential?
Its use was episodic, the patient population was small, specialist administration was required, and clinicians had alternative biochemical, imaging, and invasive localization methods.
Could ACTHREL be relaunched?
A relaunch is technically possible, but commercial success would depend on validated sterile peptide supply, FDA regulatory strategy, reimbursement, and sufficient demand from specialized endocrine centers.
References
-
U.S. Food and Drug Administration. (1999). Acthrel (corticorelin ovine triflutate) injection prescribing information. FDA.
-
National Library of Medicine. (n.d.). DailyMed: Acthrel, corticorelin ovine triflutate injection. DailyMed.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008). The diagnosis of Cushing's syndrome: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 93(5), 1526-1540.
-
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021). Consensus on diagnosis and management of Cushing's disease: A guideline update. The Lancet Diabetes & Endocrinology, 9(12), 847-875.
